- Haemonetics Announces Proposed Convertible Senior Notes Offering
- Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
- Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
- Haemonetics Corporation Completes Acquisition of Attune Medical
- Haemonetics Announces Definitive Agreement to Acquire Attune Medical
More ▼
Key statistics
On Wednesday, Haemonetics Corp (HAE:NYQ) closed at 90.09, -8.04% below its 52-week high of 97.97, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 87.74 |
---|---|
High | 91.19 |
Low | 86.00 |
Bid | 87.66 |
Offer | 96.74 |
Previous close | 93.19 |
Average volume | 552.77k |
---|---|
Shares outstanding | 50.79m |
Free float | 50.37m |
P/E (TTM) | 40.74 |
Market cap | 4.73bn USD |
EPS (TTM) | 2.29 USD |
Data delayed at least 15 minutes, as of May 23 2024 00:00 BST.
More ▼